TherapeuticsMD (TXMD) Tops Q3 EPS by 2c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
TherapeuticsMD® Announces Third Quarter 2020 Financial Results
November 9, 2020 6:55 AM ESTSignificant growth in net revenue, net revenue per unit and prescriptions across product portfolio
Total net revenue increased 80% to $19.3 million compared to 2Q20
ANNOVERA® net revenue increased 250% for 3Q20 compared to 2Q20
Menopausal products achieved double digit growth in new and total prescriptions for 3Q20 compared to 2Q20
Reduced 3Q20 cash burn by $22 million compared to 2Q20
Process to divest vitaCare Prescription Services underway that could generate non-dilutive proceeds
Sixth Street reduces minimum cash requirement from... More
